Par's Xalatan Generic Delayed Until 2011 Under Patent Ruling
This article was originally published in The Pink Sheet Daily
Executive Summary
Two of three Pfizer patents for the glaucoma treatment are valid, a Trenton, N.J. federal court says. If the court's ruling is affirmed on appeal, Par would lose any 180-day generic marketing exclusivity that attaches to the two valid patents.
You may also be interested in...
Xalatan Patent Ruling
A D.C. federal appeals court upheld a patent ruling that bars Par from launching its generic of Pfizer's glaucoma agent Xalatan before 2011
Xalatan Patent Ruling
A D.C. federal appeals court upheld a patent ruling that bars Par from launching its generic of Pfizer's glaucoma agent Xalatan before 2011
Teva Accupril Generic Delayed Until 2007; Pfizer Patent Is Valid, Court Says
If upheld on appeal, the decision would eliminate Teva’s 180-day exclusivity period and make a challenge to Pfizer’s own generic moot. A New Jersey federal judge finds there was no inequitable conduct before the PTO regarding Pfizer’s patent for its ACE inhibitor.